April, 2024
April 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Karen Knudsen: It is such an honor to be named to the inaugural CNBC Change makers list alongside these incredible women
Mar 4, 2024, 17:53

Karen Knudsen: It is such an honor to be named to the inaugural CNBC Change makers list alongside these incredible women

Karen Knudsen shared a post by CNBC on LinkedIn:

”It is such an honor to be named to the inaugural CNBC Change makers list alongside these incredible women! This is a testament to the important work that our team at the American Cancer Society and American Cancer Society Cancer Action Network (ACS CAN) is doing to accelerate progress toward our vision to end cancer as we know it, for everyone.

Thank you to all of our team members, partners, and volunteers who help make the work we do possible!”

Quoting CNBC’s post:

”The women named to the inaugural CNBC Change makers list are setting the standard for what it takes to defy the odds, innovate and thrive in a volatile business landscape. See the full 2024 CNBC Changemakers list here.”

Video attached.
Source: Karen Knudsen/LinkedIn and CNBC/LinkedIn

Karen E. Knudsen is the CEO of the American Cancer Society (ACS) and its advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN). Prior to joining ACS, Dr. Knudsen served as executive vice president of Oncology Services and enterprise director for Sidney Kimmel Cancer Center at Jefferson Health. She also served as president for the Association of American Cancer Institutes (AACI), representing the 102 leading cancer centers in North America, and on the board of directors of the American Association for Cancer Research (AACR).

Dr. Knudsen currently holds leadership roles with some of the most important cancer entities in the United States. She serves on the board of advisors for the National Cancer Institute and on 12 external advisory boards for NCI-designated cancer centers. She is an active member of several committees with the American Society for Clinical Oncology (ASCO), in addition to serving on other academic and for-profit advisory boards.